3Tepel M, Aspelin P, Lameire N. Contrast-induced nephropathy:a clinical and evidence-based approach [ J]. Circulation, 2006 ; 113 (14) :1799- 806.
4Briguori C, Airoldi F, Morici N, et al. New pharmacological protocols to prevent or reduce contrast media nephropatby[J]. Minerva Cardioangial, 2005 ;53( 1 ) :49-58.
5Cavusoglu ES, Chhabra JD, Marmur A, et al. The prevention of contrast induced nephropathy in patients undergoing percutaneous coronary intervention[J]. Minerva C',n'dioangiol,2004;52(5) :419-32.
6Cowbum PJ, Patel H, Pipes RR, et al. Contrast nephropathy post cardiac resynchronization therapy:an under recognized complication with important morbidity[ J]. Eur J Heart Fail,2005 ;7 ( 15 ) :899-903.
7Merten GJ, Burgess WP, Gray LV, et al. Prevention of contrast-induced nephropathy with sodium bicarbonate:arandomized controlled trial [ J]. JAMA,2004 ;291 ( 19 ) :2328-34.
8Brar SS, Shen AY, Jorgensen MB, et al. Sodium bicarbonate vs sodium chloride for the prevention of contrast medium-induced nephropathy in patients undergoing coronary angiography:a randomized trial[J]. JAMA ,2008 ;300(9 ) : 1038-46.
9Perazella MA. Drug-induced renal failure: Update on new medications and unique mechanisms of nephrotoxicity [ J ]. Am J Med, 2003 ; 325 ( 1 ) :349-62.
10Whehon A. Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications[J]. Am J Meal, 1999; 106 (5B) : 13S-24S.
